Nomigren (Almotriptan)

Almotriptan is a triptan class medication used to treat migraine-related conditions.

• Migraine without aura: aborts acute migraine attacks and relieves headache pain.
• Migraine with aura: provides rapid relief of headache phase following aura.
• Acute migraine attacks: reduces associated symptoms such as nausea, photophobia, and phonophobia.

• Almotriptan selectively binds to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. Activation of these receptors induces vasoconstriction of intracranial arteries and inhibits the release of vasoactive neuropeptides, thereby interrupting the cascade that generates migraine pain and associated symptoms.

Common and serious adverse reactions have been reported with Almotriptan.

Common Side Effects

• Nausea: mild to moderate feeling of stomach upset.
• Dizziness: transient light‑headedness or vertigo.
• Fatigue: unusual tiredness after dosing.
• Dry mouth: reduced salivation leading to throat discomfort.
• Tingling sensations: paresthesia in extremities.
• Somnolence: mild drowsiness.

Serious or Rare Side Effects

• Chest pain: possible cardiac discomfort requiring evaluation.
• Serotonin syndrome: rare but severe condition with agitation, hyperthermia, and muscle rigidity.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Hypertension: unexpected rise in blood pressure.
• Cardiac arrhythmia: irregular heart rhythm events.

Before prescribing Almotriptan, clinicians should consider several safety measures.

• Assess cardiovascular risk: evaluate history of coronary artery disease before prescribing.
• Avoid use with ergot derivatives: concurrent use may increase vasospasm risk.
• Caution in uncontrolled hypertension: monitor blood pressure closely.
• Do not combine with MAO inhibitors: risk of serotonin excess.
• Store at room temperature: keep in the original pack, protect from moisture.

Almotriptan may interact with other medications, requiring attention to avoid adverse effects.

Major Interactions (Avoid)

• MAO inhibitors: increase risk of serotonin syndrome.
• SSRIs, SNRIs, or other serotonergic agents: may precipitate serotonin toxicity.
• Ergotamine or dihydroergotamine: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: possible additive blood pressure lowering.
• Oral contraceptives: may reduce efficacy of migraine relief.
• CYP3A4 inhibitors (e.g., ketoconazole): may increase Almotriptan plasma levels.